Royal Peptides Review (2026): FDA Letter, Lab Reports, Finnrick

Royal Peptides is the store at royal-peptides.com. Its public product data listed 141 products on 2 November 2026, across single vials and 10-vial kits, and takes crypto and Cash App. The Bureau has no affiliate program with this store, so nothing on this page links to it for commission.

This review scores it from public evidence read on 2 November 2026: the store's product data, its published policies, its certificate vault, reports opened at the lab, Finnrick and the FDA record. The Bureau did not create an account or place an order.

Who runs it and how it sells

FDA's letter addresses Royal Peptides LLC at a suite in Boynton Beach, Florida. The Bureau did not find that address on the store pages it read. The About page says the store was founded in 2023 and has warehouses in the US, Canada and the EU. Whois shows the domain was created on 20 August 2024, which does not match the 2023 claim, though an earlier brand or domain could exist.

Finnrick's vendor report (13 June 2026) says it found no matching entity in the registries it searched, and rates the risk of identity misrepresentation as high. It also describes a 2024 site archive naming Chinese manufacturing partners, since removed, and a mostly undisclosed affiliate and coupon layer. The Bureau did not verify those points, and FDA's later letter does name a Florida LLC.

What the FDA letter says

The letter is reference MARCS-CMS 734884, from the Center for Drug Evaluation and Research. FDA reviewed royal-peptides.com in July 2026 and found that "Tirzepatide", "Semaglutide", "Retatrutide", "SS-31 (Elamipretide)", "PT-141", "Tesamorelin" and "BIMORELIN" are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act. It cites the product pages plus two comparison articles.

A footnote says that despite research-use statements, the evidence shows intended human use. FDA points to bacteriostatic water marketed alongside a peptide guide and a peptide calculator as part of that evidence. The letter asked for a response within 15 business days and warned of seizure and injunction.

The limits again. The letter concerns how products were marketed and sold. It is not a test of the vials and does not say any lot failed. The Bureau found no close-out letter or public response on 2 November 2026, and a response may be in progress and not public. But the store's public product data on that date still listed all seven, and the store pages the Bureau fetched did not mention the letter.

What the certificates show

The certificate vault (modified 26 October 2026) lists 32 compounds, 62 linked reports and 71 batch records across five labs. Many entries show only a band such as "99%+" instead of a figure, and vault batch codes do not match the lots printed on the PDFs exactly.

The Bureau opened four of the linked reports at Janoshik on 2 November 2026. All four are in the lab's database. Look at the client column.

The vault's only BPC-157 report does not carry Royal's name. It names CHP as the client and Champion Peptide as the manufacturer. The retatrutide 10 mg report names JP for both. Neither report says how those names relate to Royal, and the two October reports leave manufacturer and batch blank, so they cannot be tied to a lot. Finnrick's report says the site warns that certificates may show upstream manufacturers, aliases or distributors. That could explain it, but it means these two reports show a sample somebody sent, not a vial that can be traced to Royal.

Another name turns up on a Freedom Diagnostics PDF: an SS-31 50 mg report names its client as "PEPETIDES XBT", and two others show a single letter. The Bureau could not explain those either.

Fill runs high. Freedom reports read as PDFs show TB-500 10 mg at 12.78 mg (about 28% over), tirzepatide 30 mg at 37.90 mg (about 26% over), and SS-31 50 mg at 58.44 mg (about 17% over). A fill above label is not a purity problem, but a label that far off is an accuracy problem. The peptide testing guide covers what a lot report should contain.

What independent testing found

Finnrick tests vials that buyers send in. On 2 November 2026 it listed 34 tests, 25 of 34 classifiable tests passing, a 75% rating and 235th of 489 vendors. The latest test was a tirzepatide pass on 25 August 2026.

That is the strongest part of the case for this store, and better than several other stores the Bureau has reviewed outside its scorecard. Two details limit it. Finnrick calls retatrutide volatile, and its June report records a 40 mg vial dated 29 January 2026 that held 11.4 mg, plus a second 40 mg short-fill on 1 March 2026. And it has no BPC-157 test, so the one BPC-157 report above is all the evidence there is for that compound.

Prices, against the scored vendors

Single-vial prices from the store's product pages on 2 November 2026, with its "20% off all GLPs" sale already applied, against Amino Club, the Bureau's top-scored vendor, read by the Bureau's price tracker on 1 November. Both before any code.

Royal is cheaper on retatrutide, by about $1 a mg at 10 mg and nearly $2 a mg at 30 mg. It is about level on semaglutide and GHK-Cu, and dearer on the rest, including BPC-157 and TB-500. Crypto takes a further 10% off, per the store. Today's prices at every vendor the Bureau reviews are on the price tracker; the retatrutide, BPC-157 and TB-500 guides compare the scored vendors that stock each.

Shipping, payment and returns

All as the store states them. It ships from US, Canada or EU warehouses, which it says are "not guaranteed", with tracking once a label is created. The home page says same-day shipping, worldwide, and free over $300 for US orders. The Bureau found no cut-off time and placed no order.

The policy page, modified 25 October 2026, says sales are generally final, with no returns or exchanges. Damage or error claims need photos and all the packaging, and remedies run from replacement or store credit to a partial or full refund. Payment guides cover crypto and Cash App. Whether cards are accepted was not established.

Reputation signals the Bureau could source

Regulators. The FDA letter above. A web search on 2 November 2026 found no Justice Department case. Absence from a search is not a clean bill.

Trustpilot. The profile for royal-peptides.com showed as removed on 2 November 2026. Trustpilot gives no store-specific reason, so nothing more should be read into it. The store's own reviews page shows 4.9 across 298 reviews, but it is self-published and moderated, so it does not count here.

Google. The second result for the store's name is the FDA letter. Several other results on that page are spam on unrelated domains.

Royal Peptides coupon codes

There is no Peptide Bureau code for Royal Peptides. The store's coupon page, modified 12 January 2026, describes ROYAL10 as a public code for 10% off sitewide. The Bureau has not tested it. For the vendors where the Bureau does hold a working code, the peptide coupon codes page lists each one with the date it was last tested.

Is Royal Peptides legit?

It sells real product by the test record, but too much cannot be traced. A 75% Finnrick rating over 34 tests is a genuine point in its favour, and on retatrutide the price is low.

The score sits at 2.6 because the FDA letter is ten weeks old and every named product is still for sale, the BPC-157 and retatrutide 10 mg reports do not carry the store's name, Finnrick records severe short-fills, and a buyer has little recourse with final sales.

Who it suits. A researcher set on retatrutide price who has read the short-fill record and the FDA letter. Who it does not. Anyone buying BPC-157, where there is no independent test and the report names someone else. Amino Club, in the box below, lists it for less.

What would move the score

Up: reports under the store's own name with a lot number on every line; a BPC-157 record at Finnrick; a public FDA close-out; a real return option.

Down: further FDA action, more short-fills, or evidence that reports do not match what ships.

Score breakdown

How each line was reached: COA transparency credits a large vault, several labs and reports that are real at the lab, less other clients' names on the BPC-157 and retatrutide 10 mg reports, bands instead of figures, batch codes that do not match and large overfills. Shipping reflects stated multi-region dispatch that is not guaranteed, no cut-off time and crypto-first payment, with no order of our own. Consistency credits a 75% rating over 34 tests and a recent pass, less volatile retatrutide with short-fills and no BPC-157 test. Customer service reflects final sales, heavy proof for claims and no independent review figure. Pricing credits low retatrutide against dearer core compounds. Longevity reflects a domain from August 2024, a fresh FDA letter on listed products, an unverified operator and a look-alike store.

Scoring methodology: documentation checks against published COAs, independent test databases, store prices, published terms and public-reputation cross-checks; reader orders where we have them, which for this vendor we do not yet. Full criteria on the methodology page and the listing policy. No vendor has ever paid for placement or score.

Frequently Asked Questions

Is Royal Peptides legit?

Royal Peptides at royal-peptides.com is a real store, and its Finnrick record is mid-table at 75%. It scores 2.6 out of 5 because FDA sent it a warning letter in August 2026 on seven products it still lists, its BPC-157 lab report names a different client, sales are generally final, and Finnrick could not verify its operator.

Did the FDA warn Royal Peptides?

Yes. A letter dated 24 August 2026, reference 734884, told Royal Peptides LLC that tirzepatide, semaglutide, retatrutide, SS-31, PT-141, tesamorelin and BIMORELIN are unapproved new drugs. All seven were still in the store's public product data on 2 November 2026. The Bureau found no close-out or public response.

Are Royal Peptides lab reports real?

The four the Bureau opened at Janoshik on 2 November 2026 are in the lab's database. Two October 2026 reports name Royal Peptides. The BPC-157 report names CHP as client and Champion Peptide as manufacturer, and the retatrutide 10 mg report names JP. The reports do not explain how those names relate to Royal.

Is royalpeptidesusa.com the same store?

Royal's own page says royal-peptides.com is its only official site and that royalpeptidesusa.com and royalpeptides.ca are not operated by it. That is Royal's statement. Who runs the other sites is not established. This review covers royal-peptides.com only.

What did Finnrick find on Royal Peptides?

On 2 November 2026 Finnrick listed 34 tests, 25 passing, a 75% rating and 235th of 489 vendors. Tirzepatide rated 80%, semaglutide 74% and retatrutide 70%. Finnrick's June report describes retatrutide as volatile, including a 40 mg vial that held 11.4 mg. BPC-157 has no Finnrick tests from this store.

Is ROYAL10 a working Royal Peptides coupon code?

The store's coupon page, modified 12 January 2026, describes ROYAL10 as a public code for 10% off sitewide. The Bureau has not tested it and holds no code of its own for this store.

Research use only. The compounds discussed are sold as research chemicals and are not approved for human use. Nothing here is medical advice.